CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 174 enrolled
Drug / intervention
Magnesium Isoglycyrrhizinate Injection 100mg OD +2 moredrug
Likely dose
Magnesium Isoglycyrrhizinate Injection 100mg ODfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02734966
NCT02734966Phase 2Completed
CompareCT.gov

A Multi-center, Randomized, Double-blind, Active Control Phase II Study to Investigate Multiple Dosage and Treatments of Magnesium Isoglycyrrhizinate Injection to Cure the Acute Drug-induced Liver Injury

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·interventional·Posted Apr 12, 2016·Updated Sep 27, 2016

In Brief

A Phase 2 clinical trial evaluating Magnesium Isoglycyrrhizinate Injection 100mg OD, Magnesium Isoglycyrrhizinate Injection 200mg OD, and 1 other intervention for Drug-Induced Liver Injury. Completed, enrolled 174 participants across 8 sites.

Detailed Summary

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug-Induced Liver Injury
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 12, 2016
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2008
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.2 years ago

Interventions

Magnesium Isoglycyrrhizinate Injection 100mg ODdrug

Magnesium Isoglycyrrhizinate Injection 100mg OD

Magnesium Isoglycyrrhizinate Injection 200mg ODdrug

Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks

Tiopronin Injectiondrug

Tiopronin Injection 200mg OD